Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
Our centers are performing as expected or even better
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
Vonoprazan is a potassium-competitive acid blocker (P-CAB) used for the treatment of acid-related disorders
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
